Vivacelle Bio’s VBI-S Phase IIa clinical trial meets primary and secondary endpoints for treating hypovolemia in septic shock patients
Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.